A Registry for Patients With Systemic Mastocytosis in China
Mastocvtosis Collaborative Network of China: A Registry for Patients With Systemic Mastocytosis
1 other identifier
observational
150
1 country
1
Brief Summary
The Registry for Patients With Systemic Mastocytosis in China is a voluntary, observational database that will capture demographic, socioeconomic, and disease information with systemic mastocytosis. No experimental intervention is involved.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 23, 2023
CompletedFirst Posted
Study publicly available on registry
August 28, 2023
CompletedStudy Start
First participant enrolled
September 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2025
CompletedOctober 10, 2023
October 1, 2023
2 years
July 23, 2023
October 7, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
The morbidity rate over 2 years ofSystemic Mastocytosis and its subtypes (cases per 1,000 individuals per year)
Evaluation of the morbidity rate over 2 years of Systemic Mastocytosis and its subtypes including Bone marrow mastocytosis (BMM), Indolent SM, Smoldering SM, Aggressive SM, SM with an associated hematologic neoplasm and Mast cell leukemia. (cases per 1,000 individuals per year)
at 2 year
Secondary Outcomes (5)
Demographic characteristics of Systemic Mastocytosis
at 2 year
Hematological characteristics of Systemic Mastocytosis
at 2 year
Nonhematological characteristics of Systemic Mastocytosis
at 2 year
Responses to therapy of Systemic Mastocytosis
at 2 year
Survival Distribution of Systemic Mastocytosis
at 2 year
Eligibility Criteria
Patients with a diagnosis of systemic mastocytosis according to World Health Organization (WHO) classification, including subtypes of SM, who is willing and able to provide written online informed consent.
You may qualify if:
- \. Any patient with a diagnosis of systemic mastocytosis according to World Health Organization (WHO) classification, including subtypes of SM, who is willing and able to provide written online informed consent.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Suzhou, Jiangsu, 215006, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Suning Chen, Professor
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Clinical Professor
Study Record Dates
First Submitted
July 23, 2023
First Posted
August 28, 2023
Study Start
September 1, 2023
Primary Completion
August 31, 2025
Study Completion
August 31, 2025
Last Updated
October 10, 2023
Record last verified: 2023-10